Lymphodepletion and tumor burden govern clinical responses in patients with B-cell malignancies treated with autologous, CD19-targeted T cells.
R. J. Brentjens
No relevant relationships to disclose
I. Riviere
No relevant relationships to disclose
J. Park
No relevant relationships to disclose
M. Davilla
No relevant relationships to disclose
X. Wang
No relevant relationships to disclose
R. Yeh
No relevant relationships to disclose
N. Lamanna
No relevant relationships to disclose
M. G. Frattini
No relevant relationships to disclose
M. Sadelain
No relevant relationships to disclose